DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...
DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...
TipRanks on MSN
Citi ups DexCom target, adds 'upside 90-day catalyst watch'
Citi raised the firm’s price target on DexCom (DXCM) to $77 from $75 and keeps a Buy rating on the shares. Citi also opened an “upside 90-day catalyst watch” on DexCom. The firm sees the stock moving ...
Bernstein raised the firm’s price target on DexCom (DXCM) to $89 from $86 and keeps an Outperform rating on the shares as part of a broader research note indicating that the firm is positive on 2025 ...
Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...
Raymond James lowered the firm’s price target on DexCom (DXCM) to $99 from $115 and keeps a Strong Buy rating on the shares. DexCom’s Q3 results provided modest upside to consensus, but Raymond James ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Shares in Dexcom plunged in extended trading Thursday after the medical devices company ...
Morgan Stanley analyst Patrick Wood upgraded the stock to Overweight from Equal Weight on Tuesday, citing a favorable ...
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. After ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results